DCDB 2.0: a major update of the drug combination database

Experience in clinical practice and research in systems pharmacology suggested the limitations of the current one-drug-one-target paradigm in new drug discovery. Single-target drugs may not always produce desired physiological effects on the entire biological system, even if they have successfully regulated the activities of their designated targets. On the other hand, multicomponent therapy, in which two or more agents simultaneously interact with multiple targets, has attracted growing attention. Many drug combinations consisting of multiple agents have already entered clinical practice, especially in treating complex and refractory diseases. Drug combination database (DCDB), launched in 2010, is the first available database that collects and organizes information on drug combinations, with an aim to facilitate systems-oriented new drug discovery. Here, we report the second major release of DCDB (Version 2.0), which includes 866 new drug combinations (1363 in total), consisting of 904 distinctive components. These drug combinations are curated from ∼140 000 clinical studies and the food and drug administration (FDA) electronic orange book. In this update, DCDB collects 237 unsuccessful drug combinations, which may provide a contrast for systematic discovery of the patterns in successful drug combinations. Database URL: http://www.cls.zju.edu.cn/dcdb/

[1]  Young Suk Park,et al.  Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study , 2009, Cancer Chemotherapy and Pharmacology.

[2]  Hongkang Mei,et al.  Systematic Prediction of Pharmacodynamic Drug-Drug Interactions through Protein-Protein-Interaction Network , 2013, PLoS Comput. Biol..

[3]  References , 1971 .

[4]  Guan-Hua Lai,et al.  Celecoxib acts in a cyclooxygenase-2-independent manner and in synergy with emodin to suppress rat cholangiocarcinoma growth in vitro through a mechanism involving enhanced Akt inactivation and increased activation of caspases-9 and -3. , 2003, Molecular cancer therapeutics.

[5]  H. Chandler Database , 1985 .

[6]  Razelle Kurzrock,et al.  Combining Erlotinib and Cetuximab Is Associated with Activity in Patients with Non–Small Cell Lung Cancer (Including Squamous Cell Carcinomas) and Wild-Type EGFR or Resistant Mutations , 2013, Molecular Cancer Therapeutics.

[7]  K. Coleman,et al.  In vitro synergistic properties of clavulanic acid, with ampicillin, amoxycillin and ticarcillin. , 1980, The Journal of antimicrobial chemotherapy.

[8]  Tianhan Xue,et al.  Studying Traditional Chinese Medicine , 2003, Science.

[9]  Xiaohua Ma,et al.  Mechanisms of drug combinations: interaction and network perspectives , 2009, Nature Reviews Drug Discovery.

[10]  K. Fizazi,et al.  The role of Src in prostate cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  Yang Song,et al.  Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery , 2011, Nucleic Acids Res..

[12]  Olivier Bodenreider,et al.  The Unified Medical Language System (UMLS): integrating biomedical terminology , 2004, Nucleic Acids Res..

[13]  Kyoung Mii Park,et al.  CDA: Combinatorial Drug Discovery Using Transcriptional Response Modules , 2012, PloS one.

[14]  Joel Dudley,et al.  Network-Based Elucidation of Human Disease Similarities Reveals Common Functional Modules Enriched for Pluripotent Drug Targets , 2010, PLoS Comput. Biol..

[15]  J Henkel,et al.  Attacking AIDS with a 'cocktail' therapy? , 1999, FDA consumer.

[16]  Henning Hermjakob,et al.  The Reactome pathway Knowledgebase , 2015, Nucleic acids research.

[17]  Jiehua Zhu,et al.  National Natural Science Foundation of China (NSFC) , 2013 .

[18]  T. Chou Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[19]  David S. Wishart,et al.  DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..

[20]  David Pérol,et al.  Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. , 2011, The Lancet. Oncology.

[21]  S. Hursting,et al.  Obesity, metabolic dysregulation, and cancer: a growing concern and an inflammatory (and microenvironmental) issue , 2012, Annals of the New York Academy of Sciences.

[22]  Enrique Casado,et al.  Chemotherapy for colorectal cancer in the elderly: Whom to treat and what to use. , 2009, Cancer treatment reviews.

[23]  Michele Magrane,et al.  UniProt Knowledgebase: a hub of integrated protein data , 2011, Database J. Biol. Databases Curation.

[24]  Doheon Lee,et al.  Systematic Approach for Analyzing Drug Combination by Using Target-Enzyme Distance , 2013 .

[25]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[26]  Susumu Goto,et al.  Data, information, knowledge and principle: back to metabolism in KEGG , 2013, Nucleic Acids Res..

[27]  Chris Sander,et al.  Drug Synergy Screen and Network Modeling in Dedifferentiated Liposarcoma Identifies CDK4 and IGF1R as Synergistic Drug Targets , 2013, Science Signaling.

[28]  Ravi Iyengar,et al.  Systems Pharmacology of Adverse Event Mitigation by Drug Combinations , 2013, Science Translational Medicine.

[29]  Joaquim Bellmunt,et al.  Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. , 2013, The Lancet. Oncology.

[30]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[31]  Matthew Sperrin,et al.  Investigation of the robustness of two models for assessing synergy in pre-clinical drug combination studies. , 2013, Pharmaceutical statistics.

[32]  Rafael C. Jimenez,et al.  The MIntAct project—IntAct as a common curation platform for 11 molecular interaction databases , 2013, Nucleic Acids Res..

[33]  Alan R. Aronson,et al.  An overview of MetaMap: historical perspective and recent advances , 2010, J. Am. Medical Informatics Assoc..

[34]  Erika Martinelli,et al.  Synergistic Effects of Metformin Treatment in Combination with Gefitinib, a Selective EGFR Tyrosine Kinase Inhibitor, in LKB1 Wild-type NSCLC Cell Lines , 2013, Clinical Cancer Research.

[35]  Xin Chen,et al.  Human interactome resource and gene set linkage analysis for the functional interpretation of biologically meaningful gene sets , 2013, Bioinform..

[36]  Eunyoung Kang,et al.  Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR) , 2014, BMC Cancer.

[37]  Liang Liu,et al.  Network-based drug discovery by integrating systems biology and computational technologies , 2012, Briefings Bioinform..

[38]  Lei Huang,et al.  DrugComboRanker: drug combination discovery based on target network analysis , 2014, Bioinform..

[39]  Yanli Wang,et al.  PubChem applications in drug discovery: a bibliometric analysis. , 2014, Drug discovery today.

[40]  J. Lehár,et al.  Systematic discovery of multicomponent therapeutics , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Axel Hauschild,et al.  Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha‐2b in metastatic melanoma (phase II DeCOG trial) , 2013, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[42]  F. Sörgel,et al.  Effect of probenecid on the distribution and elimination of ciprofloxacin in humans , 1995, Clinical pharmacology and therapeutics.

[43]  Luke A. Gilbert,et al.  Defining principles of combination drug mechanisms of action , 2012, Proceedings of the National Academy of Sciences.

[44]  Tudor I. Oprea,et al.  Drug Repurposing from an Academic Perspective. , 2011, Drug discovery today. Therapeutic strategies.

[45]  Bo Zhang,et al.  Network target for screening synergistic drug combinations with application to traditional Chinese medicine , 2011, BMC Systems Biology.